COMMUNIQUÉS West-GlobeNewswire

Spyre Therapeutics to Participate in Upcoming March Investor Conferences
24/02/2026
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of [...]
Aktis Oncology to Present at Upcoming March Investor Conferences
24/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient [...]
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
24/02/2026
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
24/02/2026
SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
24/02/2026
- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 – - Advancement reflects continued execution of capital-efficient [...]
Capital Increase in Genmab as a Result of Employee Warrant Exercise
24/02/2026
Company Announcement COPENHAGEN, Denmark; February 24, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,313 shares as a consequence of the exercise of employee warrants. The increase is effected [...]
Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer
24/02/2026
SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced [...]
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
24/02/2026
MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted [...]
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
24/02/2026
OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January [...]
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
24/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
24/02/2026
$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively BridgeBio reported three [...]
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
24/02/2026
Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products [...]
Rapport Therapeutics to Participate in Upcoming Investor Conferences
24/02/2026
BOSTON and SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
24/02/2026
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
24/02/2026
Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and [...]
Palvella Therapeutics Announces Proposed Public Offering
24/02/2026
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat [...]
Merit Medical Reports Fourth Quarter and Full Year 2025 Results and Issues Fiscal Year 2026 Guidance
24/02/2026
Fourth Quarter Highlights† Reported revenue of $393.9 million, up 11% Constant currency revenue* and constant currency revenue, organic* up 10% and up 7%, respectively GAAP operating margin of 13.8%, compared to 10.3% [...]
AB Science annonce l'identification d'un biomarqueur plasmatique marqueur de l'activité du masitinib dans le traitement de la SLA
24/02/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE L'IDENTIFICATION D'UN BIOMARQUEUR PLASMATIQUE MARQUEUR DE L'ACTIVITÉ DU MASITINIB DANS LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE, ET CAPABLE D'IDENTIFIER LES PATIENTS [...]
Surgery Partners, Inc. Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details
24/02/2026
BRENTWOOD, Tenn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will [...]

Pages